When facing a cancer diagnosis, patients at MU Health Care’s Ellis Fischel Cancer Center can benefit from a team of experts working together to find the right solution for their unique needs.
Dedicated cancer specialists regularly band together to discuss new or challenging cases. These meetings, known as tumor boards, bring together a variety of experts with different focus areas and perspectives — all determined to use precision medicine to come up with the most personalized and effective treatment plan possible.
“We’ve all heard that two heads are better than one. Well, what if we have 15 people in the room, all devoted to a person’s case?” said MU Health Care pathologist Richard Hammer, MD. “Having experts each with their own niche specialty come together means we can evaluate every angle to develop the best treatment plan.” Not all diseases affect each patient the same way. Based on a person’s or a cancer’s genetics, a cancer may affect one person differently than another. Tumor boards are a forum for the team to discuss a patient’s unique variations, with the goal of designing the most effective therapies and treatment plans to not only treat the cancer, but to prevent it from coming back, as well.
Clinicians and researchers at MU Health Care are using the most advanced technology in these forums to help design their treatment plans. In collaboration with the pharmaceutical and diagnostics company Roche, MU Health Care is the first U.S.-based institution to pilot the NAVIFY™ Tumor Board solution.
The tool streamlines the flow of information, putting crucial data — radiology and microscope slide images, pathology reports, electronic medical records and more — directly in front of cancer doctors. This standardization saves time that would otherwise be spent manually gathering test results and charts from different sources. Results have shown that NAVIFY™ gives the care team better data and more time for in-depth discussions as it develops personalized treatment plans.
Not only do clinicians have more time to discuss a case, they will soon have another tool to provide them with specific treatment recommendations unique to a person’s own biology.
“This spring, we will be able to use NAVIFY™ to incorporate data from FoundationOne, a genetic profiling tool that looks at mutations in different types of cancer,” Hammer said. “We will be able to see in real time genetic testing results of the cancer and will have access to treatment recommendations designed to work with a patient’s cancer unique molecular variations. It will really streamline how we approach cancer care and will give us the best options possible to beat cancer.”
While the technology streamlines tumor boards across various specialties, providers are exploring ways to use NAVIFY™ to proactively improve the health of populations. They are looking forward to not only the immediate impact on patients, but also how the technology may evolve to help prevent people from developing certain cancers altogether.
“When we have a better understanding of a cancer’s genetic mutations, we can develop treatments that will be the most effective with as few side effects as possible,” said Kevin Staveley-O’Carroll, MD, PhD, director of Ellis Fischel Cancer Center. “Beyond just sequencing a patient’s cancer genes, we will one day soon be able to extend our approach and look at a person’s individual microbiome, or the bacteria in their gut. If we can understand how a patient’s specific bacteria interact with certain foods, we may be able to boost the body’s natural immune response to help target tumors.”
The precision medicine currently offered at MU Health Care is part of a bigger initiative to make health care as personalized and effective as possible. With the upcoming opening of the NextGen Precision Health Institute, researchers and doctors will be able to better understand diseases and conditions as they relate to an individual’s genetics, lifestyle and environment. With that level of understanding and the resources offered at the NextGen Institute, the University of Missouri and MU Health Care will be able to take discoveries even further, developing treatment and prevention strategies that not only save and improve lives in Missouri, but also share findings to help others across the globe.
The precision medicine research conducted at the MU School of Medicine is part of NextGen Precision Health, an initiative to expand collaboration in personalized health care and the translation of interdisciplinary research for the benefit of society. The Roy Blunt NextGen Precision Health building at Mizzou anchors this statewide initiative, which aims to unite government and industry leaders with innovators from across the system’s four research universities in pursuit of life-changing precision health advancements. The University of Missouri System’s bold NextGen initiative highlights the promise of personalized health care and the impact of large-scale interdisciplinary collaboration.